A new type of CB1 drug reduces THC withdrawal symptoms in mice

A CB1 positive allosteric modulator (ZCZ011) significantly reduced physical signs of THC withdrawal in mice without causing the sedation or psychoactive effects typical of direct CB1 activators.

Trexler, K R et al.·Pharmacology·2019·Preliminary EvidenceAnimal StudyAnimal Study
RTHC-02322Animal StudyPreliminary Evidence2019RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Animal Study
Evidence
Preliminary Evidence
Sample
Not reported

What This Study Found

ZCZ011 (at 10 mg/kg and above) significantly reduced somatic withdrawal signs including head twitches and paw tremors in both precipitated and spontaneous THC withdrawal models. Importantly, ZCZ011 did not affect locomotor activity and did not produce conditioned place preference, suggesting it lacks the rewarding and sedating properties of direct CB1 agonists.

Key Numbers

THC dose: 10 mg/kg. ZCZ011 effective at 10 mg/kg and above. Rimonabant precipitating dose: 3 mg/kg. ZCZ011 also blocked NSAID-induced gastric ulcers when combined with 1 mg/kg JZL184.

How They Did This

Mice were repeatedly administered THC (10 mg/kg) then withdrawal was either precipitated with rimonabant or allowed to occur spontaneously via THC abstinence. ZCZ011 was tested at multiple doses. Additional experiments tested ZCZ011 for anti-ulcer properties.

Why This Research Matters

Cannabis withdrawal is increasingly recognized as a clinical problem. A drug that eases withdrawal without producing its own psychoactive effects or abuse potential could be a useful treatment tool.

The Bigger Picture

Allosteric modulators represent a newer pharmacological approach that fine-tunes receptor activity rather than fully activating or blocking it, potentially offering better safety profiles for cannabinoid-based treatments.

What This Study Doesn't Tell Us

Animal study only (mice). Effects may not translate to humans. THC withdrawal in mice presents differently than in humans. No cognitive outcomes measured.

Questions This Raises

  • ?Would CB1 positive allosteric modulators reduce withdrawal symptoms in humans?
  • ?Could this approach also help manage tolerance to medical cannabis?

Trust & Context

Key Stat:
Reduced withdrawal without sedation or reward
Evidence Grade:
Well-designed animal study with multiple experimental models, but no human data.
Study Age:
2019 preclinical study.
Original Title:
CB1 positive allosteric modulation attenuates Δ9-THC withdrawal and NSAID-induced gastric inflammation.
Published In:
Pharmacology, biochemistry, and behavior, 177, 27-33 (2019)
Database ID:
RTHC-02322

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / Observational
Case Report / Animal StudyOne case or non-human subjects
This study

Tests effects in animals (usually mice or rats), not humans.

What do these levels mean? →

Frequently Asked Questions

Is there a medication for cannabis withdrawal?

Not yet approved for humans, but this animal study showed a CB1 positive allosteric modulator reduced physical withdrawal signs in mice without causing sedation or its own abuse potential.

What is an allosteric modulator?

Rather than directly activating or blocking a receptor, an allosteric modulator binds to a different site and fine-tunes how the receptor responds to its natural signals, potentially offering more targeted effects with fewer side effects.

Read More on RethinkTHC

Cite This Study

RTHC-02322·https://rethinkthc.com/research/RTHC-02322

APA

Trexler, K R; Eckard, M L; Kinsey, S G. (2019). CB1 positive allosteric modulation attenuates Δ9-THC withdrawal and NSAID-induced gastric inflammation.. Pharmacology, biochemistry, and behavior, 177, 27-33. https://doi.org/10.1016/j.pbb.2018.12.009

MLA

Trexler, K R, et al. "CB1 positive allosteric modulation attenuates Δ9-THC withdrawal and NSAID-induced gastric inflammation.." Pharmacology, 2019. https://doi.org/10.1016/j.pbb.2018.12.009

RethinkTHC

RethinkTHC Research Database. "CB1 positive allosteric modulation attenuates Δ9-THC withdra..." RTHC-02322. Retrieved from https://rethinkthc.com/research/trexler-2019-cb1-positive-allosteric-modulation

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.